BI Partners with Inflammasome Therapeutics to Develop Retinal Disease Therapies

Boehringer Ingelheim (BI) and Inflammasome Therapeutics, a developer of therapies for degenerative diseases, have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. The pact combines Inflammasome’s intravitreal (IVT) drug-delivery technologies and BI’s compounds from its retinal disease pipeline portfolio with the goal of delivering new therapies for retinal diseases. 

Inflammasome is entitled to receive up to $160 million in upfront, research and development support and milestone-gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

The collaboration between BI and Inflammasome aims to use Inflammasome’s technology to deliver therapeutics for treating certain retinal diseases (age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) to deliver therapeutics in a biodegradable gel formulation into the eye.

Source: Boehringer Ingelheim

Leave a Reply

Your email address will not be published. Required fields are marked *